169 related articles for article (PubMed ID: 28680277)
21. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
[TBL] [Abstract][Full Text] [Related]
23. Applications of cardiotoxicity in breast cancer: a meta-analysis.
Rahmani H; Shahriary A; Sheikhi MA; Ebadi A; Davoodzadeh H
Panminerva Med; 2017 Mar; 59(1):90-96. PubMed ID: 27314979
[TBL] [Abstract][Full Text] [Related]
24. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F
Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233
[TBL] [Abstract][Full Text] [Related]
25. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.
Chin-Yee NJ; Yan AT; Kumachev A; Ko D; Earle C; Tomlinson G; Trudeau ME; Krahn M; Krzyzanowska M; Pal R; Brezden-Masley C; Gavura S; Lien K; Chan K
CMAJ Open; 2016; 4(1):E66-72. PubMed ID: 27280116
[TBL] [Abstract][Full Text] [Related]
26. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
27. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
28. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
[TBL] [Abstract][Full Text] [Related]
29. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.
Gómez Peña C; Dávila-Fajardo CL; Martínez-González LJ; Carmona-Sáez P; Soto Pino MJ; Sánchez Ramos J; Moreno Escobar E; Blancas I; Fernández JJ; Fernández D; Correa C; Cabeza Barrera J
Pharmacogenet Genomics; 2015 Aug; 25(8):388-93. PubMed ID: 26049584
[TBL] [Abstract][Full Text] [Related]
30. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
31. Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer.
Lu CY; Srasuebkul P; Drew AK; Ward RL; Pearson SA
Intern Med J; 2012 Nov; 42(11):1229-35. PubMed ID: 21981464
[TBL] [Abstract][Full Text] [Related]
32. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.
Mokuyasu S; Suzuki Y; Kawahara E; Seto T; Tokuda Y
Breast Cancer; 2015 Nov; 22(6):563-9. PubMed ID: 24563373
[TBL] [Abstract][Full Text] [Related]
33. Assessing Adherence to Cardiac Monitoring Guidelines in Trastuzumab-Treated Breast Cancer Patients: Insights From a Tertiary Hospital.
Alhuthali A; Alshammari A; Saleh K; Jaffal M; Bajnaid E; Almutairi MS; Almuylibi Z; Alghanmi A; Alnuhait M
Cureus; 2023 Nov; 15(11):e48832. PubMed ID: 38106693
[TBL] [Abstract][Full Text] [Related]
34. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-induced cardiotoxicity.
Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
[TBL] [Abstract][Full Text] [Related]
36. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.
Wu YY; Huang TC; Tsai TN; Chen JH; Dai MS; Chang PY; Ho CL; Ye RH; Chung TR; Chen YC; Chao TY
PLoS One; 2016; 11(3):e0151112. PubMed ID: 26953588
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
